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 Glaucoma, a progressive optic neuropathy, is character-
ized by the loss of retinal ganglions cells and their axons and
tissue remodelling involving both the optic nerve head and
the retina. This leads clinically to a visible cupping of the disc
and measurable thinning of the nerve fiber layer of the retina
(Figure 1). The patients experience progressive visual field
damage along with a decrease in contrast and color sensitivity
[1]. Increased intraocular pressure (IOP) is a major risk factor
for primary open angle glaucoma (POAG). Still, the focus on
IOP as the only risk factor leaves various questions open. Why
don’t all patients with glaucomatous damage have an elevated
IOP? Why do a majority of people with increased IOP not
develop glaucomatous optic neuropathy (GON)? Why does
the therapeutic reduction of IOP, although on average improv-
ing the prognosis of GON, not stop progression in all patients?
Why do some patients require very low, almost non-physi-
ological, IOP levels to stop progression? These observations
challenge the pathophysiological concept of glaucoma based
solely on IOP. Today, we know that other concomitant factors
such as blood flow alterations [2], and oxidative stress [3] play
an important role.
 Oxygen is the primary oxidant in metabolic reactions designed
to deliver energy from the oxidation of a variety of organic
molecules. Metabolism of oxygen by cells generates as a by-
product potentially deleterious reactive oxygen species (ROS)
[4] (Figure 2). Under optimal conditions the rate and magni-
tude of oxidant formation is balanced by the rate of oxidant
elimination through the action of antioxidants. But even in
healthy individuals excess of oxidants may cause some mac-
romolecular damage. An imbalance between prooxidants and
antioxidants, in favour of the former, however, results in oxi-
dative stress. This, in turn, may lead to damage of a variety of
macromolecules, such as proteins, lipids, sugar residues, or
DNA, and thereby leads, in extreme cases, to growth arrest,
modulation in form and function and even to death of cells.
 A more or less constant reduction of OBF within a certain
limit can be tolerated by the eye. Patients, for example, with
severe arteriosclerosis or with reduced OBF due to high level
of endothelin (e.g. due to autoimmune diseases) often have a
normal or slightly pale optic nerve head, which however is
not excavated. This indicates that tissues can actually adapt to
lower levels of oxygen. If OBF, however, is markedly reduced
an infarction will result. On the other hand, if oxygen supply
is unstable (due to fluctuation of perfusion pressure, especially
when auto-regulation is defective), oxidative stress results. In
other words a constant reduction of OBF (e.g. due to athero-
sclerosis) is a risk factor for infarction; unstable OBF, how-
ever, is a risk factor for GON.
This instability in blood flow leads to a repeated mild
reperfusion and thereby to the formation of ROS which dam-
age the mitochondria of the axons especially the mitochon-
dria of the optic nerve head (so called reperfusion injury).
This review summarizes the current evidence supporting
the role of ocular blood flow (OBF) and oxidative stress with
particular reference to interrelationships between blood flow
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224dynamics and oxidative stress in the pathogenesis of glauco-
matous damage.
DISCUSSION
The oxygen molecule:  Ground state oxygen
The oxygen molecule is thought of as the elixir of life,
and this benign image is well deserved as long as the mol-
ecule remains in its electronic ground state. This molecule
when in an electronically excited state, forming reactive oxy-
gen species, becomes delirious, in particular if in excess of
cellular antioxidant balance. The oxygen molecule in ground
state (the most stable state of oxygen), is a di-radical [5].
A free radical is an atom or a molecule with one or more
unpaired electrons in its outer shell; by gaining or loosing an
electron these molecules accommodate a much more stable
electronic configuration.
The question therefore arises as to why the oxygen mol-
ecule, a di-radical in ground state, is minimally reactive. In
ground state the oxygen molecule has two unpaired electrons,
each of which are located in a different pi* antibonding or-
bital (Figure 3). These two electrons rotate about their own
axis in parallel spins. When two free radicals fuse to an new
molecule, the electrons of the two molecules that will pair
together have different (anti-parallel) spin. Oxygen molecule
would need another molecule with two electrons with the same
spin, anti-parallel to the spin of the electrons of the oxygen
molecule. This however is very rare. Due to this “spin restric-
tion” molecular oxygen in its ground state is minimally reac-
tive.
Activation of oxygen- Oxygen can be activated by two
different mechanisms. Either, through the absorption of suffi-
cient energy to reverse the spin on one of the unpaired elec-
trons, or through monovalent reduction (Figure 4). If ground
state oxygen absorbs sufficient energy to reverse the spin of
one of its unpaired electrons, the two unpaired electrons now
have opposite spins. This activated form of oxygen, known as
singlet oxygen (1O2) is much more reactive than ground state
oxygen and reacts destructively with molecules. The second
mechanism of activation is by monovalent reduction [4]. Hy-
drogen peroxide is a molecule with a high oxidizing capacity.
In the presence of reduced transition metals (eg. ferrous or
cuprous ions) hydrogen peroxide can be converted into the
highly reactive hydroxyl radical (OH) this reaction is known
as the Fenton reaction.
Oxidative stress- The eye is a unique organ because of
its constant exposure to light, atmospheric oxygen, environ-
mental chemicals and physical abrasion. As previously men-
tioned, metabolism of oxygen by cells generates potentially
deleterious reactive oxygen species (ROS). Under optimal
conditions the rate and magnitude of oxidant formation is bal-
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Figure 1. Phenomenology of glaucomatous optic neuropathy.  Glaucoma, a progressive optic neuropathy, is characterized by the loss of retinal
ganglions cells and their axons and tissue remodelling involving both the optic nerve head and the retina. This leads clinically to a visible
cupping of the disc and measurable thinning of the nerve fiber layer of the retina. This figure is reprinted from Flammer J. Glaucoma,
Glaucoma A Guide for Patients. An Introduction for Care-Providers. A Quick Reference. 3rd ed. Cambridge: Hogrefe & Huber; 2006. Figure
S1.54; p 235.
225anced by the rate of oxidant elimination through the action of
antioxidants [6]. An antioxidant is by definition any substance
that significantly delays or prevents oxidation of a substrate.
In very simple words, an antioxidant can neutralize
prooxidants. Nature has therefore provided us with mecha-
nisms to help us cope with prooxidants. If ROS production
exceeds this capacity, however, oxidative stress damages dif-
ferent molecules. As long as nature is capable of repairing
damaged molecules (e.g., DNA) or eliminating damaged mol-
ecules (proteins via proteosomes) no major structural damage
occurs. But if oxidative stress induced-damage exceeds the
capacity of repair mechanisms, structural damage sums up and
leads, finally, to a clinically relevant damage that we call a
disease, such as glaucoma (Figure 5).
Ocular blood flow in glaucoma- The regulation of blood
flow in the eye, is different in different tissues. The regulation
of retinal blood flow is very similar to the regulation of blood
flow in the brain, with the exception that retinal vessels have
no autonomic innervation and therefore its regulation depends
even more on the activity of endothelium cells. These cells
release a number of factors, the so-called endothelium derived
vasoactive factors (EDVFs) [7], which on one hand regulate
the size of the vessels by influencing vascular smooth muscle
cells locally, and on the other hand, via intraluminal release of
these factors lead to changes in blood rheology (e.g., by influ-
encing platelet aggregation) and influence the size of the ves-
sels globally. In addition, both the neural and glial cells, also
influences the size of the vessels. This is known as neurovas-
cular coupling. If flickering light for e.g. hits the eyes, the
vessels dilate within seconds [8]. The exact mechanism of this
regulation is not yet known. It is known, however, that the
production of nitric oxide (NO) is involved.
The regulation of blood flow of the choroid is very differ-
ent from that of retinal blood flow [2]. The choroidal vessels
are extensively autonomically innervated and the capillaries
are fenestrated. Besides providing oxygen and other molecules
to the retina, the choroid regulates the temperature of the back
of the eye and most probably contributes to the fine tuning of
accommodation by regulation of volume. The regulation of
temperature can be demonstrated, for e.g., with the observa-
tion that when moving from a warm to a cold environment,
the choroidal blood flow increases within seconds. If we put
one drop of local anesthetics in one eye, but not in the other,
the eye that received the local anesthetic drop will adapt much
less. The cold response is mediated by cold receptors in the
sclera.
Blood flow in the optic nerve head is regulated some-
what similarly to that of the retina with the important excep-
tion that no efficient blood brain barrier exists in the optic
nerve head [9]. As a consequence circulating molecules such
as vasoactive hormones, enzymes, or even drugs, get access
to the smooth muscle cells and pericytes of the vessels in the
optic nerve head.
On average, blood flow is reduced in glaucoma patients
in various tissues of the eye, including the iris, retina, optic
nerve and choroids [2,10,11]. Blood flow reduction is even
more pronounced in normal tension glaucoma than in high
tension glaucoma. Interestingly, reduction in blood flow can
also be observed in the nailfold capillaries of fingers of glau-
coma patients, indicating that this reduction is not only due to
an increase in IOP or glaucomatous damage. There must be a
primary component of blood flow dysfunction and this, in turn,
is due to a global vascular dysregulation.
Vascular dysregulation syndrome:  What is vascular
dysregulation?
In biology any cell but also any organ or any living or-
ganism must constantly adapt to different environments. This
is the reason why only organisms with a good regulation sur-
vived evolution. For regulation of any parameter several sys-
tems are involved in a way that dysfunctioning of any one of
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Figure 2. Risks and consequences
of oxidative stress.  The eye is an
organ that is predisposed to great
levels of oxidative stress. The eye
is constantly exposed to factors such
as radiation, chemicals, oxygen,
drugs, which induce the formation
of reactive oxygen species (ROS)
that can ultimately damage cells.
This figure is modified from
Flammer J. Glaucoma, Glaucoma A
Guide for Patients. An Introduction
for Care-Providers. A Quick Refer-
ence. 3rd ed. Cambridge: Hogrefe
& Huber; 2006. Figure S1.29; p 222.
226the systems would lead to compensation by another. Further-
more, the regulations of different parameters are often inter-
related. Blood flow, for example, is involved in the regulation
of oxygen supply, transport of temperature and volume regu-
lation. This explains why a basic dysregulation, such as a vas-
cular dysregulation, leads to many different and seemingly
unrelated symptoms.
The vascular system is highly regulated on different lev-
els such as on large or small arteries, capillaries and veins. A
dysregulation simply means that this local adaption is not ac-
cording to the need of the body or its corresponding tissues.
This may have local reasons, such as damage of the endothe-
lium cells by rupture of an atherosclerotic plaque. An inflam-
mation of the vessel walls also hinders the local adaption. In
this context, however, we are going to discuss the more sys-
temic types of dysregulation. These can be grouped in a pri-
mary vascular dysregulation (PVD) and a secondary vascular
dysregulation (SVD). In the context of glaucoma, PVD is more
important as we shall see later on in this review. We will there-
fore just summarize some of the aspects of SVD and then de-
scribe PVD in more
Secondary vascular dysregulation- A secondary
dysregulation is due to other diseases; quite often, autoim-
mune diseases. Patients with a secondary vascular
dysregulation normally have high level of circulating
Endothelin. The high level of Endothelin leads to a reduction
of blood flow both in the choroid and the optic nerve head
[12-14]. It does not, however, interfere with autoregulation
which is why secondary vascular dysregulation remains a
minor risk factor for glaucomatous damage.
As mentioned before the endothelial cells release vaso-
active substances not only abluminally, to regulate local resis-
tance, but also intraluminally to induce an overall effect. This
effect is very different from one organ to the other due to the
fact these substances, while having access to endothelial cells
in all organs, have direct access to smooth muscle cells and
pericytes only in organs with fenestrated capillaries such as
the choroid and thereby also indirectly to the optic nerve head.
Physiologically Endothelin is produced by endothelial
cells. Under pathological conditions, however, any cell under
marked stress can produce Endothelin and thereby contribute
to the level of endothelin in the circulating blood [15-19]. For
example, in patients with arthritis the synovial cells produce
Endothelin, in multiple sclerosis the lymphocytes and finally
in AIDS the macrophages etc.
Primary vascular dysregulation- Subjects with a pri-
mary vascular dysregulation (PVD) syndrome have an inborn
tendency to respond differently to various stimuli such as cold,
mechanical or emotional stress and others [20]. Affected sub-
jects also exhibit differences for e.g. in sleep behavior, feeling
of thirst, drug sensitivity etc., as will be discussed below. While
they can hardly be distinguished from others under baseline
conditions, they respond differently to stimuli such as cold,
mechanical or psychological stress, etc. Among the most ap-
parent pathological reactions are the vasoconstrictions giving
rise to the previously used term “vasospastic syndrome” [21].
But why do these subjects constrict their vessels more than
others?
Subjects with a PVD have a normal capacity to produce
ATP and are, therefore, physically seen as strong as the oth-
ers. Under certain circumstances, however, where these sub-
jects do not use as much ATP, such as when they sit quietly in
a cold environment, they are not able to produce as much heat
as others. This is one of the reasons why these subjects con-
strict the vessels in their extremities: to reduce heat loss. In-
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Figure 3. Electron configuration of the diatomic oxygen molecule.
Atomic oxygen (atomic number 8) has a total of eight electrons. The
oxygen molecule (O2) has 16 electrons. In ground state (the most
stable state of oxygen), the last two electrons of the oxygen molecule
are located in a different π* antibonding orbital. These two unpaired
electrons have the same quantum spin number (they have parallel
spins) and qualify ground state oxygen to be a di radical.
Figure 4. Different energy levels of oxygen and oxygen compounds.
Activation of oxygen occurs either through absorption of sufficient
energy or through monovalent reduction.
227terestingly, as they constrict the vessels in their skin they also
constrict the vessels in the back of their eyes.
The PVD syndrome occurs more frequently in females
than in males [22], in Japanese than in Caucasians [23,24],
and in academics than in blue collar workers [25]. It remains
unclear why women suffer more often from PVD than men.
The symptoms are normally first manifested in puberty and
mitigate with age.
There are various clinical signs that indicate a PVD. Sub-
jects with a PVD often have cold extremities like cold hands
or feet [26], they tend to have normal or low body mass indi-
ces [27], the feeling of thirst is often reduced (they drink be-
cause they know they have to drink and not so much because
they are thirsty) [28], they tend to have low blood pressure
especially when they are young [29], they more often suffer
from migraines than non-PVD subjects [30] (although PVD
and migraine are two distinct entities). PVD subjects have often
an altered drug sensitivity due to differential expression of
ATP-Binding Cassette (ABC) transporter proteins [31]. They
have, on average, a longer sleep onset time, especially when
they are cold [32]. They often have a meticulous personality
and are often successful in their professions [33].
The regulation of OBF in patients with PVD is different:
morphologically the retinal vessels demonstrate a higher level
of irregularity [34]. When stimulated by flicker light they re-
spond with a smaller vasodilation than normals [8]. In a provo-
cation with hand-grip test (a stimulation of the sympathetic
nervous system) their choroidal vessels constrict more than
normals [35]. Vessels in vasospastic subjects conduct pulse
waves faster and are thus stiffer than those in nonvasospastic
subjects [36]. PVD subjects have a disturbed autoregulation
[37] very similar to glaucoma patients that progress despite a
normal or normalized IOP [38].
Dysfunction of regulation leads to an unstable ocular per-
fusion especially when IOP or blood pressure fluctuates. The
resulting instability of blood flow leads to a repeated, but very
mild, reperfusion contributing via oxidative stress to glauco-
matous damage. This seems to be a key factor and will there-
fore be discussed below [39].
Reperfusion injury:  What is reperfusion injury?
Reperfusion injury refers to damage to tissue caused when
blood supply returns to the tissue after a period of ischemia.
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Figure 6. The pathogenetic
concept of glaucomatous optic
neuropathy.  Oxidative stress
results from unstable ocular
blood flow (OBF). OBF is un-
stable both in patients with ei-
ther high IOP or very low
blood pressure (BP) exceeding
the capacity of autoregulation,
as well as in patients with a
normal or mildly increased IOP
or normal or mildly decreased
blood pressure if subjects suf-
fer from disturbed autoregula-
tion. This figure is reprinted
from Flammer J. Glaucoma,
Glaucoma A Guide for Pa-
tients. An Introduction for
Care-Providers. A Quick Ref-
erence. 3rd ed. Cambridge:
Hogrefe & Huber; 2006. Fig-
ure 5.12; p 104.
Figure 5. Oxidative stress and disease.  In the physiological state, the
production of prooxidants is approximately balanced by the antioxi-
dant defence system. The term oxidative stress is referred to when
the intensity of prooxidants exceed the antioxidant capacity.
228The absence of oxygen and nutrients from the blood creates a
condition in which the restoration of circulation results in in-
flammation and oxidative damage through the induction of
oxidative stress rather than restoration of normal function.
In POAG, oxygen tension in the tissue often falls tempo-
rarily. This drop is very mild, but recurrent over years. To some
extent, such a drop of oxygen leads to an adaptation which is
called preconditioning. This makes the cell more resistant to
coming drops of oxygen. If the drop of oxygen exceeds a cer-
tain limit, reperfusion damage is induced. When the oxygen
drop is even larger or lasts longer tissue infarction results. This
occurs rarely in glaucoma but as a consequence of other dis-
eases.
Reperfusion injury inducing glaucomatous optic neu-
ropathy (GON)- Reperfusion occurs both in patients with
either high IOP or very low blood pressure exceeding the ca-
pacity of autoregulation, as well as in patients with a normal
or mildly increased IOP or normal or mildly decreased blood
pressure if subjects suffer from disturbed autoregulation.
Recurrent mild reperfusion leads to a chronic oxidative
stress, especially in the mitochondria. Mitochondria are very
crowded in the optic nerve head due to high energy consump-
tion in the active area lacking myelin sheets. The mitochon-
dria get more and more damaged and making energy supply
less and less efficient. But also other cellular compartments
suffer and undergo a sort of accelerated aging process. In par-
allel activated astrocytes change the microenvironment. To-
gether a pathogenesis is induced which shall be discussed later
on in this review [40] (Figure 6).
Oxidative stress and glaucoma:  Oxidative stress and in-
traocular pressure (IOP)
Oxidative stress has been implicated to be a cause of in-
creased intraocular pressure by triggering trabecular meshwork
(TM) degeneration and thus contributing to alterations in the
aqueous outflow pathway [41,42]. The TM is in constant con-
tact with the aqueous humor from which ROS may be gener-
ated through light catalyzed reactions, metabolic pathways or
inflammation [41,43-45]. Disturbance of the TM cell sta-
tus by an insult such as oxidative stress, may lead to cellular
loss and an over expression or alteration in the structures of
the TM, in particular in the extracellular matrix [46-48], lead-
ing to impaired aqueous humor outflow and thereby an in-
crease in IOP.
The pathogenic role of oxidative stress in increasing IOP
is supported by various studies. In vitro treatment of human
TM cells with hydrogen peroxide alters cellular adhesion and
integrity [46]. In an animal study of calf, perfusion of TM
cells with peroxide has shown to reduce aqueous humor drain-
age from the anterior chamber of the eye [49]. In humans,
DNA damage has been reported to be significantly higher in
the TM cells of glaucoma patients than in those of age-matched
controls [50]. Further studies demonstrate abundant oxidative
nucleotide modification (8-OH-dG) levels in human TM to
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Figure 8. Comet assay analy-
sis of lymphocytes.  A: Photo-
graph of the present equipment
used. B: a typical picture of the
DNA of a lymphocyte ana-
lyzed by the system. The
greater the amount of DNA
breaks, the larger the comet
tail.
Figure 7. Production of peroxynitrite.  The simultaneous production
of the readily diffusible nitric oxide (NO) in glial cells and the super-
oxide anion (O2-) in the axons of the retinal ganglion cells leads to
the production of peroxynitrite (ONOO-). This figure is reprinted from
Flammer J. Glaucoma, Glaucoma A Guide for Patients. An Introduc-
tion for Care-Providers. A Quick Reference. 3rd ed. Cambridge:
Hogrefe & Huber; 2006. Figure 5.13; p 105.
229be significantly correlated to the increase in IOP and to visual
field damage [49,51]. Glaucoma patients display a significant
depletion of total antioxidant potential in their aqueous hu-
mor [52], a decrease in plasmatic glutathione levels [53], and
an increase in serum antibodies against glutathione-S- trans-
ferase [54]. Heat shock proteins act as molecular chaperones
protecting the three dimensional structure of other proteins.
The heat shock protein, αB-crystalline was shown to be overly
expressed in TM cells of both human and monkey eyes stressed
by heat [55]. In vitro studies have shown that enhanced ex-
pression of αB-crystalline confers cellular thermoresistance
[56] and protection against oxidative stress [57]. The mecha-
nisms by which αB-crystalline performs these functions are
still not clear. In glaucoma heat shock proteins are upregulated
supporting indirectly the role of oxidative stress. In glaucoma,
over expression of heat shock proteins may be a consequence
of oxidative stress [55].
Oxidative stress and glaucomatous optic neuropathy
(GON)- The observation that the majority of glaucoma pa-
tients show signs of reduced ocular blood flow (OBF) as well
as ischemic signs in the eye (eg. upregulation of the ischemia
inducible factor 1-α) [58], indicates that other factors, in par-
ticular hemodynamic factors are involved in the pathogenesis
as well [2].
OBF is, however, also reduced in a number of other dis-
eases as for example in multiple sclerosis [18], (due to a high
level of circulating endothelin) [15], indicating that ischemia
by itself does not induce GON. Even patients with a carotid
stenosis do not suffer significantly more often from GON [59].
While on the one hand, glaucoma patients have reduced
OBF and this OBF reduction even has a predictive power for
the progression of GON [60], on the other hand, a blood flow
reduction by artherosclerosis, multiple sclerosis or by a high
level of endothelin-1 (eg. multiple sclerosis), do not increase
the risk for GON significantly. The only way to explain this is
simply the fact that it is not a stable reduction in OBF but
rather the instability in blood flow that may lead to GON [2].
Such an instablity in OBF leads to a repeated mild reperfusion
injury [39]. Reperfusion injury in glaucoma patients, particu-
larly in the optic nerve head is very mild but occurs repeat-
edly [39]. This hypothesis of the reperfusion injury being in-
volved in the pathogenesis of GON is supported by the obser-
vation that IOP fluctuation is more damaging than a stable
increase in IOP [61-63], and by observations that patients that
progress despite a normalized IOP suffer from a disturbed
autoregulation [38]. The main cause for this insufficient auto-
regulation, as previously mentioned, is a primary vascular
dysregulation (PVD) syndrome [20].
We also mentioned that recurrent mild reperfusion leads
to a chronic oxidative stress, which in turn, damages all types
of molecules and thereby reduces the probability of cellular
survival. Still, the question arises as to why in glaucoma spe-
cifically the retinal ganglion cells and their axons die by
apoptosis. Both ischemic and mechanical stress lead to an ac-
tivation of astrocytes. Once activated, astrocytes start produc-
ing a variety of molecules, one of which is nitric oxide (NO).
NO although having a very short half-life, has a small size
and is liposoluble and can therefore readily diffuse to neigh-
boring cells such as the axons of the optic nerve head (ONH).
If simultaneously as a result of reperfusion, the concentration
of superoxide (O2
-) is high, the very damaging peroxynitrite is
produced [64] (Figure 7). Both superoxide anions and
peroxynitrite are water soluble and can therefore not diffuse
out of an intact cell membrane. We hypothesize that they dif-
fuse within the axons both towards the retina and the lateral
geniculate nucleus. In fact, nitrosylation of SH groups have
been found in the retina and in the lateral geniculate nucleus
indicating the presence of peroxynitrite. The assumption of
reperfusion injury being involved in the pathogenesis also
explains why sleep apnoe [65] or reversible shock-like states
[66] can lead to GON.
Signs of oxidative stress- Various signs indicate that oxi-
dative stress plays an important role in the pathogenesis of
GON. If we rely on the fact that oxidative stress occurs, we
would expect increased number of DNA breaks, an
upregulation of Endothelin-1 (ET-1), an upregulation of
metalloproteinase-9 (MMP-9), and increased activity of
proteosomes. This is indeed all the case as described below.
Analysis of DNA breaks by means of comet assay in the
circulating lymphocytes revealed an increase in DNA breaks
in glaucoma patients compared to age-matched controls [67]
(Figure 8). The increase in DNA breaks may partially be due
to an increase in oxidative stress damaging DNA but also par-
tially due to a slow down of DNA repair. The latter view is
supported by the observation that there is a reduced expres-
sion of the Xeroderma pigmentosum gene (XPGC) in glau-
coma patients [68].
Oxidative stress also leads to an unspecific increase in
endothelin-1 (ET-1). Various studies have demonstrated an
increase in ET-1 in glaucoma subjects, in particular in patients
that progress despite normalized IOP [69]. Metalloproteinases
(MMP-2 and MMP-9) are upregulated in the optic nerve head
of glaucoma patients. There is an upregulation of MMP-9 even
in circulating lymphocytes [70]. The upregulation of MMP-9
not only fits the hypothesis of reperfusion injury, but also ex-
plain various steps in the pathogenetic process of GON. Oxi-
dative stress damages a variety of molecules including pro-
teins. Unlike damaged DNA, damaged proteins cannot be re-
paired. Nature has developed sophisticated methods to elimi-
nate damaged intracellular proteins. These proteins are first
marked by ubiquitin and then pulled electrostatically into the
proteosomes where they are cut in pieces which are then re-
cycled. The activity of the proteosomes therefore gives us an
indirect measure of proteins damaged. Indeed, the expression
of 20S proteosome alpha subunit is upregulated in glaucoma,
further supporting the hypothesis of an oxidative stress [71].
These pro-apoptotic conditions observed in the circulat-
ing lymphocytes would theoretically lead to a reduced half
life of these leukocytes. Fortunately nature has built in a pro-
tective mechanism. The genes known to induce apoptosis,
namely P21WAF1/CIP1 and 14-3-3 sigma, were observed to be
down-regulated as a result of hypermethylation of DNA [67].
Conclusions:  The exact mechanisms that lead to damage
of the trabecular meshwork and thereby to an increase in IOP,
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230in POAG are still unknown. The pathogenesis leading to GON
is also only partially known. Obviously there are a number of
factors and mechanisms involved. These factors are most likely
interrelated, as in a “complex network”. So it not the question
as to whether a glaucomatous damage is more likely due to
one or the other factor (e.g., pressure versus vascular factors)
but rather a question as to how these and other factors play
together in an individual patient. One of these factors is ocu-
lar blood flow. The other, is oxidative stress. Unfortunately,
we have still only a vague idea as to how oxidative stress is
brought about in glaucoma and how it damages the tissue.
The elucidation of these factors will lead to the development
of new treatment strategies [72-76].
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